{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-003896","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.103822+00:00","generated_at":"2026-06-18T00:37:14.941436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alzamend Neuro Q3 net loss widens to $5.4M; cash $7.4M; clinical milestones on track","bullets":["Net loss $5.4M ($0.06/share) vs $2.6M ($0.03/share) a year ago; R&D spend rose to $2.9M.","Cash $7.4M at Jan 31, 2023; expects $14.8M non-dilutive note receivable in Dec 2023.","Phase IIA topline for AL001 (Alzheimer's) expected June 2023; Phase I/IIA for ALZN002 to start March 2023.","Working capital $5.8M; net cash used in operations $6.7M in nine months."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-003896","json":"https://secwatch.observer/filing/0001214659-23-003896.json","markdown":"https://secwatch.observer/filing/0001214659-23-003896.md","text":"https://secwatch.observer/filing/0001214659-23-003896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923003896/0001214659-23-003896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923003896/b3162308k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:37:14.941436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec58fa47cd3d2799428fc31525732a246d5329e3","claim":"Alzamend Neuro, Inc. reported third quarter ended January 31, 2023 results: net income $5.4 million, or $0.06 per share.","evidence_excerpt":"Net loss for the three months ended January 31, 2023 was $5.4 million, or $0.06 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923003896/0001214659-23-003896-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended January 31, 2023"},{"label":"Net income","value":"$5.4 million, or $0.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}